Metelitsa V I, Ostrovskaia T P, Duda S G, Filatova N P, Vygodin V A
Ter Arkh. 1995;67(6):15-20.
A multicenter randomized controlled trial was performed to compare antihypertensive effects and tolerance of captopril monotherapy with those of reference drugs from three other main groups of antihypertensive drugs: propranolol, hydrochlorothiazide, nifedipine. The trial included 345 males with essential hypertension stage I-II by WHO criteria. Evaluable patients after 8 months of treatment comprised 85.8%. 8-month monotherapy with captopril, nifedipine, hydrochlorothiazide and propranolol was completed by 53.49%, 75.28%, 45.78% of patients, respectively. An antihypertensive effect was reached in 57.97% of patients on monotherapy. Normalization of arterial pressure took place in 51.3%. The 4 drugs in the given doses produced a significant and similar effect in relation to the action on arterial pressure (absolute value). As for individual effects (complete and partial), captopril and propranolol were equal, nifedipine was more beneficial than hydrochlorothiazide. Side effects in captopril monotherapy arose 1.5-2 times less frequently than in response to propranolol or nifedipine and were similar to those of hydrochlorothiazide.
开展了一项多中心随机对照试验,比较卡托普利单药治疗与其他三类主要抗高血压药物(普萘洛尔、氢氯噻嗪、硝苯地平)的参考药物的降压效果和耐受性。该试验纳入了345名符合WHO标准的I-II期原发性高血压男性患者。治疗8个月后可评估的患者占85.8%。分别有53.49%、75.28%、45.78%的患者完成了8个月的卡托普利、硝苯地平、氢氯噻嗪和普萘洛尔单药治疗。单药治疗的患者中有57.97%达到了降压效果。51.3%的患者血压恢复正常。给定剂量的这4种药物对动脉压(绝对值)的作用产生了显著且相似的效果。至于个体效果(完全和部分),卡托普利和普萘洛尔相当,硝苯地平比氢氯噻嗪更有益。卡托普利单药治疗的副作用出现频率比普萘洛尔或硝苯地平少1.5至2倍,且与氢氯噻嗪的副作用相似。